Log in
This UoA has developed the largest independent simulation laboratory in the world for pre-clinical evaluation of the wear of artificial joints, which has been used to develop and commercialise novel pre-clinical simulation systems for joint replacements, in partnership with Simulation Solutions Ltd. Simulation Solutions Ltd is now the market leader of joint simulation systems outside North America.
We have also co-developed lower wearing ceramic-on-ceramic and ceramic-on-metal bearings for hip joints, and have worked with DePuy Orthopaedics Inc to define lower wearing tribological solutions for polyethylene knees. This work has benefited hundreds of thousands of patients worldwide during the REF period.
The University of Southampton's world-leading record in bioengineering continues to deliver significant benefits, resulting from recent research crucial to the development, pre-clinical verification and CE-marking of a revolutionary hip-resurfacing implant. In the wake of growing concerns over some previous implant designs, this work has positively impacted on a wide range of audiences: over 9800 patients have received the new implants with excellent early clinical results at two years' follow-up. Within 4 years UK PLC benefited with considerable additional turnover [exact figure removed for publication], a majority from abroad, and the technology attracted three years of investment for a start-up company at Southampton Science Park. This award-winning knowledge transferring research has been widely acknowledged as an example of best practice, and has increased appreciation of science and technology further through outreach.
Research at University of Oxford led to the development of the Phase 3 Oxford Knee in 1998, a significantly improved and less invasive knee replacement, allowing implantation through a small incision. Due to its many advantages over other knee replacements, including faster recovery, fewer complications and better function, the Phase 3 Oxford Knee is now the most widely used partial knee replacement in the world. Approximately 1 million people have benefitted from this development.
Over 100,000 hip joint replacements are performed each year in the UK. The correct restoration of joint centre is critical to the successful outcome of total hip replacements. Failure to do so results in dislocation, increased wear and leg length discrepancy.
In collaboration with QUB, over 4,000 patient-specific custom hip prostheses were manufactured and implanted at Musgrave Park Hospital, Belfast, leading to accurate restoration of anatomical joint centre.
As a consequence a new surgical instrument has been developed and utilised in more than 4,000 surgeries. Surgical costs are reduced compared to the alternative of computer-aided surgery. The DePuy Synthes Companies are funding the development of a later version of this surgical instrument
The high failure rate of metal-on-metal hip implants led to worldwide concern. Collaborative research between Newcastle University and University Hospital of North Tees identified design features that are considered to have contributed to the failure. The research helped to inform policy makers both nationally, such as the Medicines and Healthcare products Regulatory Agency (MHRA), and internationally, such as the US Food and Drug Administration (FDA). The final outcome was a worldwide withdrawal of one design of implant (the DePuy ASR) and a ban in several countries of a set of implants sharing common features (large head metal-on-metal total hip replacements). The research has reduced the risk of harm to patients who will now receive products with a significantly lower failure rate, and will have financial implications for implant manufacturers and healthcare providers.
Research into the field of metal-on-metal (MoM) arthroplasty (joint replacement) conducted at the University of Bristol in conjunction with the National Joint Registry of England and Wales (NJR) has led to a fundamental change in the practice of arthroplasty around the world and in the clinical follow up of patients. High failure rates have been identified nationally in England and Wales for MoM total hip arthroplasty and certain designs of resurfacing arthroplasty in work conducted by our department. Deleterious systemic effects of wear debris produced by these implants have also been identified by our research. The use of these devices has declined from 14% of procedures in 2008 to less than 1% in 2012. Citing our research, national bodies including NICE (2014), the MHRA (2011 & 2012), the UK Department of Health (2012), British Orthopaedic Association (2011 & 2012), NJR (2012), British Hip Society (2011 & 2012) and the US Food and Drug Administration (FDA) (2013) have issued guidance suggesting the restricted use of such devices or close surveillance of patients in whom these devices have been implanted.
UCL research into metal-on-metal (MOM) hip replacements has developed evidence affecting the 1.5 million patients with MOM hips worldwide and led, indirectly, to a change in the regulation of all medical devices by the US Food and Drug Administration and the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Direct impacts include stimulation of the first global retrieval programme for medical implants, [text removed for publication], and the development of a change in the MHRA protocol used to monitor all UK MOM hip patients. These have led to improvements in the quality of patients' lives after redo surgery, and supported litigation cases worth billions of dollars against health providers — including Johnson & Johnson — to fund compensation and earlier-than-expected redo hip operations. Public awareness of issues with MOM hips has been stimulated through widespread media coverage and creation of information resources by charities and regulatory bodies.
This case concerns the impact of research carried out at the Durham Centre for Biomedical Engineering on compliant layer lubricated artificial joints, which mimic natural human joints and have been used by a commercial company (Active Implants, USA) to develop specific products namely "TriboFit" and "NUsurface" conservative hip and knee replacement systems. Our underpinning technology has allowed them to produce a successful range of products. To date 1300 patients in Europe, Israel and Australia have received the "TriboFit" devices and about 90 patients are taking part in a $10M clinical trial on the "NUsurface" artificial meniscus for the knee.
Our research has developed improved hip replacement fixation techniques, which have improved the biomechanical stability of implanted artificial joints. These techniques have been employed by orthopaedic surgeons, for example at Mid-Essex Hospitals Services Trust (MEHT), in primary and revision total hip replacement operations. As a result, the number of patients requiring revision hip surgery due to cup loosening has fallen by 50%. Additionally, these techniques have reduced the recovery time per operation by 3-5 days, which in addition to benefitting the patient have also resulted in an average saving per operation of £1,200.
Metal-on-metal hip resurfacing was developed in the 1990s to provide a long-term solution for young, active patients with hip disease. After observing severe adverse soft tissue reactions (pseudotumours) occurring in a growing percentage of patients with metal-on-metal resurfacing, researchers from the University of Oxford highlighted the problem and identified key patient, surgical and implant related risk factors. Clinical guidelines have been introduced to emphasise the risks, and several implants have been withdrawn from the market by the manufacturers. This research has led to a dramatic decrease in the use of metal-on-metal bearings in hip replacement.